louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01668225: Impact of Follicular and Blood G-CSF During a Natural Cycle of IVF
Official title: Impact of Follicular and Blood G-CSF on Pregnangcy and Implantation Rate During Modified Natural in Vitro Fertility Cycle
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Infertility
Lead sponsor: Clinique Ovo
Sponsor class: INDUSTRY
First posted: 2012-08-20
Enrollment: 152
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 43
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women with a natural cycle of an In Vitro Fecondation

Brief summary: Recently, scientists look into G-CSF (Granulocyte - Colony Stimulatin Factor). The use of this molecule is increasing in reproduction pathology. High level of follicular and blood G-CSF on the day of oocyte retrieval could correlate with higher pregnancy and implantation rates.


Eligibility criteria: Inclusion Criteria:

* Women between 18 and 43 years old
* Women natural In Vitro Fecondation

Exclusion Criteria:

* No exclusion criteria

Primary outcomes:
measure: Serum and / or follicular minimum level of G-CSF predictive of pregnancy
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Montréal
country: Canada
facility: Ovo Fertilité
state: Quebec
Study officials:
affiliation: Clinique Ovo
name: Jacques Kadoch, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00859625: The Impact of Active Nurse Participation on Adenoma Detection During Routine Colonoscopy
Official title: The Impact of Active Nurse Participation on Adenoma Detection During Routine Colonoscopy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Adenoma
Keywords: colonoscopy
adenoma detection rate
Lead sponsor: Yale University
Sponsor class: OTHER
First posted: 2009-03-11
Enrollment: 500
Sex: ALL
Minimum age (years): 30
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Hypothesis-- Nurse observation in addition to the colonoscopist while withdrawing the colonoscope from the cecum leads to a greater adenoma detection rate.

Methods- Patients presenting for screening colonoscopy are randomized to nurse observation or usual practice. Risk factors for adenoma development and the adenoma detection rate in each group will be evaluated.


Eligibility criteria: Inclusion Criteria:

* performance of screening colonoscopy

Exclusion Criteria:

* history of inflammatory bowel disease, gastrointestinal bleeding

Primary outcomes:
measure: Adenoma detection rate
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale-New Haven Hospital
state: Connecticut
Study officials:
affiliation: Yale University
name: Harry Aslanian, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rogart JN, Siddiqui UD, Jamidar PA, Aslanian HR. Fellow involvement may increase adenoma detection rates during colonoscopy. Am J Gastroenterol. 2008 Nov;103(11):2841-6. doi: 10.1111/j.1572-0241.2008.02085.x. Epub 2008 Aug 27.
Clinical trial NCT06916325: Open Label Trial of Deceased Donor Livers Transplanted After DHOPE With eXVIVO LIVER Perfusion
Official title: DeLIVER Trial: A Prospective, Multi-Center, Single-Arm, Open Label Trial of Deceased Donor Livers Transplanted After DHOPE With eXVIVO LIVER Perfusion
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Liver Transplant Surgery
Liver Transplantation
Lead sponsor: XVIVO Perfusion
Sponsor class: INDUSTRY
First posted: 2025-04-08
Enrollment: 215
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this clinical study is to confirm the safety and effectiveness of dual hypothermic oxygenated perfusion (DHOPE) using the Liver Assist to preserve deceased donor livers for transplantation.


Eligibility criteria: Participant Inclusion Criteria:

1. Participant is able to provide informed consent and HIPAA authorization
2. Age ≥18 years
3. Participant is registered as an active first-time liver transplant candidate on the United Network for Organ Sharing (UNOS) waiting list for primary liver transplantation

   - For participants with hepatocellular carcinoma (HCC) as indication for Orthotopic Liver Transplantation, the tumor must be within Milan Criteria or down-staged to Milan Criteria at the time of transplant
4. Participant is willing to comply with the study requirements and procedures

Participant Exclusion Criteria:

1. Participant will undergo concurrent multi-organ transplantations (liver-kidney, liver-lung, etc.)
2. Participant is listed for liver transplantation due to fulminant liver failure (UNOS status 1A)
3. Participant is listed for a repeat liver transplantation (\>1 graft)
4. Participant is pregnant
5. Participant is on respiratory (ventilator dependent) and/or cardiocirculatory support (defined as mechanical circulatory support which requires at least one intravenous inotrope to maintain hemodynamics)
6. Participant is enrolled in an interventional clinical trial with an investigational drug or device
7. Presence of other medical, social, or psychological conditions that in the investigator's opinion, could limit the participant's ability to participate in the clinical trial

Primary outcomes:
measure: Incidence of Early Allograft Dysfunction
timeFrame: Day 7 (post operative)
measure: Overall graft survival
timeFrame: Day 180 (post operative)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03655925: Human Leucocyte Antigen G and Chronic Heart Failure
Official title: Plasma Levels of Human Leucocyte Antigen G in Patients With Chronic Heart Failure
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Heart Failure
Lead sponsor: University Hospital of Ferrara
Sponsor class: OTHER
First posted: 2018-08-31
Enrollment: 40
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 40 subjects with chronic stable heart failure with ejection fraction \<40, diagnosed according to the European Society of Cardiology Guidelines

Brief summary: The Human leukocyte antigen G (HLA-G) is a non-classical, major histocompatibility complex class I (MHC-I) protein that modulates the immune response, inhibiting it in most cases. Physiologically expressed in the cells of some tissues, it increases in inflammatory reactions. Inflammation appears to play an important role in the development of chronic heart failure. This study aims to evaluate the levels of soluble HLA-G in patients with heart failure and to investigate the relationships between HLA-G and other clinical-functional parameters of the disease. Investigators hypothesize that the plasma levels of HLA-G could correlate with the clinical status of heart failure and could provide indications on patient's prognosis.


Eligibility criteria: Inclusion Criteria:

* Patients with recent diagnosis of chronic heart failure as defined by the guidelines of the European Society of Cardiology (ESC) and with cardiac ejection fraction \<40.
* Clinical stability in the previous month prior to recruitment.
* Absence of coexisting autoimmune diseases.

Exclusion Criteria:

* Subjects with over one year chronic heart failure diagnosis and in clinical stability for less than 1 month.
* Presence of autoimmune diseases.

Primary outcomes:
measure: To measure plasma levels of soluble Human Leucocyte Antigen G (HLA-G) in patients with chronic heart failure (CHF)
timeFrame: Collection of whole blood at baseline, at 6 and 12 months from baseline
measure: To measure the polymorphisms of Human Leucocyte Antigen G (HLA-G) gene
timeFrame: Collection of whole blood at baseline
Secondary outcomes:
measure: To correlate the plasma levels of HLA-G with clinical-functional parameters of the chronic heart failure (CHF) in patients with CHF
timeFrame: At baseline and after 12 months
Other outcomes:
Locations:
city: Ferrara
country: Italy
facility: Department of Medical Sciences/ Medicine of Public Health
Study officials:
References:
citation: Alegre E, Rizzo R, Bortolotti D, Fernandez-Landazuri S, Fainardi E, Gonzalez A. Some basic aspects of HLA-G biology. J Immunol Res. 2014;2014:657625. doi: 10.1155/2014/657625. Epub 2014 Apr 9.
citation: Almasood A, Sheshgiri R, Joseph JM, Rao V, Kamali M, Tumiati L, Ross HJ, Delgado DH. Human leukocyte antigen-G is upregulated in heart failure patients: a potential novel biomarker. Hum Immunol. 2011 Nov;72(11):1064-7. doi: 10.1016/j.humimm.2011.08.016. Epub 2011 Sep 1.
Clinical trial NCT06710925: A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk Infants
Official title: A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Monoclonal Antibody TNM001 Injection Against Respiratory Syncytial Virus in High-risk Infants
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: Respiratory Syncytial Virus Infections
Lead sponsor: Zhuhai Trinomab Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2024-11-29
Enrollment: 201
Sex: ALL
Minimum age (years): 0
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study is a Phase 3 randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and immunogenicity of TNM001 in high-risk infants when entering their RSV season. Approximately 201 infants will be randomized in a ratio of 2:1 to receive TNM001 or placebo. All subjects will be followed for 270 days after dosing. This study will be conducted at approximately 20 sites in China.


Eligibility criteria: Inclusion Criteria:

* 1.High risk infants under 1 year of age who are entering their first RSV season at the time of screening.
* 2.Subject's legal representative(s) is(are) able to understand and comply with the requirements and procedures of the protocol,including scheduled visits and sample collection.
* 3.Subject is available to complete the follow-up period.

Exclusion Criteria:

* 1. Any fever (\> 38.0°C) or acute illness within 7 days prior to randomization
* 2. History of RSV infection
* 3. Being hospitalized at the time of randomization
* 4. Currently receiving or expected to receive immunosuppressive therapy during the study period.
* 5. Renal impairment or hepatic dysfunction
* 6. Nervous system disease or neuromuscular disease
* 7. Known immunodeficiency including HIV, mother with HIV infection unless the child's infection has been excluded.
* 8. Known allergy history of immunoglobulin products, receipt or expected to receive immunoglobulins or blood products during the study period.
* 9.Receipt of RSV vaccine or mAb
* 10.Receiving blood products before randomization

Primary outcomes:
measure: Incidence of medically attended LRTI due to RT-PCR confirmed RSV
timeFrame: 150 days post dose
Secondary outcomes:
Other outcomes:
Locations:
city: Chengdu
country: China
facility: West China Second University Hospital, Sichuan University
state: Sichuan
city: Chongqing
country: China
facility: Children's Hospital of Chongqing Medical University
state: Sichuan
Study officials:
affiliation: West China Second Hospital, Sichuan University
name: Hanmin Liu
role: PRINCIPAL_INVESTIGATOR
affiliation: Children's Hospital of Chongqing Medical University
name: Enmei Liu
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04697225: Healthy Weight at Home: A Pilot Weight Loss Program for Parents of Children With a Disability
Official title: Healthy Weight at Home: A Pilot Weight Loss Program for Parents of Children With a Disability
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Overweight and Obesity
Lead sponsor: Towson University
Sponsor class: OTHER
First posted: 2021-01-06
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective of this study is to design, implement, and pilot a lifestyle-based, 12-week, weight loss program for parents of children with a disability. This weight loss program supports weight loss among parents. It is a first step towards a parent-only approach to promote healthier weight among children with a disability.


Eligibility criteria: Inclusion Criteria:

Parent

* age ≥18
* English speaking
* completion of screening and baseline data collection
* BMI ≥ 25 and weight \< 300lbs (weight limit due to scale limitations)
* willing to lose weight through physical activity, weight tracking and decreased caloric intake
* willing to make changes at home to facilitate a healthy weight
* willing to complete 12 weekly weight loss video coaching sessions (20 minutes/session)
* willing to use Skype, FaceTime, Zoom, or WebEx for regular intervention contact
* Internet/ cellular plan that is sufficient for weekly program video conferencing
* willing to use the study scale with cellular technology to report weights at baseline, 12 weeks, and 24 weeks.
* willing to use the study scale with cellular technology at least weekly during the study (12 weeks)
* completion of screening and baseline data collection

Child

* age 8-18
* has a disability
* assent is required if the child is capable and willing to have height and weight taken by the parent at baseline, 12 weeks, and 24 weeks.

Exclusion Criteria:

* parent or child: previously diagnosed eating disorder, or treatment for an eating disorder
* parent: currently pregnant or plan to get pregnant in the next 6 months
* parent: planned weight loss surgery or procedure in the next 6 months

Primary outcomes:
measure: Weight change among the parents at week 12
timeFrame: baseline and 12 weeks
Secondary outcomes:
measure: Adherence with the scheduled weekly coaching calls
timeFrame: baseline to 12 weeks
measure: Weight change among the parents at week 24
timeFrame: baseline and 24 weeks
measure: Change in BMI z-score among the children
timeFrame: baseline, 12, and 24 weeks
Other outcomes:
Locations:
city: Towson
country: United States
facility: Towson University
state: Maryland
Study officials:
affiliation: Towson University
name: Gerald Jerome, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05670925: A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.
Official title: The Opportune Administration of Nab-paclitaxel in the First Line Treatment Strategy, Camrelizumab and Famitinib With/Without Nab-paclitaxel, of Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer：An Open, Single-arm, Multicenter Phase II Clinical Study.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Triple-Negative Breast Cancer
Lead sponsor: Fudan University
Sponsor class: OTHER
First posted: 2023-01-04
Enrollment: 46
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study is being conducted to evaluate the Opportune Administration of Nab-paclitaxel in the First Line Treatment Strategy, Camrelizumab and Famitinib with/without Nab-paclitaxel, of Patients with Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer.


Eligibility criteria: Inclusion Criteria:

* ECOG Performance Status of 0-1
* Expected lifetime of not less than three months
* Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression)
* Cancer stage: recurrent or metastatic breast cancer; Local recurrence be confirmed by the researchers could not be radical resection.
* Adequate hematologic and end-organ function, laboratory test results.
* Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) • Patients had received no previous chemotherapy or targeted therapy for metastatic triple-negative breast cancer

Exclusion Criteria:

* Previous received anti-VEGFR small molecule tyrosine kinase inhibitors (e.g. famitinib, sorafenib, Sunitinib, regorafenib, etc.) for treatment of the patients .
* A history of bleeding, any serious bleeding events.
* Important blood vessels around tumors has been infringed and high risk of bleeding.
* Coagulant function abnormality
* artery/venous thromboembolism event
* History of autoimmune disease
* Positive test for human immunodeficiency virus
* Active hepatitis B or hepatitis C
* Uncontrolled pleural effusion and ascites • Known central nervous system (CNS) disease.
* Long-term unhealing wound or incomplete healing of fracture
* urine protein ≥2+ and 24h urine protein quantitative \> 1 g.
* Pregnancy or lactation.
* Thyroid dysfunction.
* Peripheral neuropathy grade ≥2.
* People with high blood pressure;
* A history of unstable angina;
* New diagnosis of angina pectoris.
* Myocardial infarction incident ;

Primary outcomes:
measure: PFS
timeFrame: max 24 months
Secondary outcomes:
measure: ORR
timeFrame: 8 WEEKS
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center Shanghai, China, 200032
state: Shanghai
Study officials:
References:
Clinical trial NCT05059925: Structured Gym Activities and Aerobic Activities in People With Cardiac Conditions
Official title: Compare the Effects of Structured Gym Activities and Traditional Aerobic Activities in People With Cardiac Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiac Disease
Keywords: Gym Activities
Aerobic Exercises
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2021-09-28
Enrollment: 72
Sex: ALL
Minimum age (years): 30
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: To compare the effect of structured gym activities and traditional aerobic activities on cardiorespiratory endurance in people with cardiac conditions To compare the effect of structured gym activities and traditional aerobic activities on quality of life in people with cardiac conditions


Eligibility criteria: Inclusion Criteria:

* Individuals with cardiac conditions including post-first myocardial infarction, post valvular diseases, post-CABG patients.
* Individuals who can perform cardiorespiratory exercises with ease(who are able to complete 6 minute walk test).
* Individuals who have not performed regular physical activity in the past 6 months (PA-R)
* No regular exercise or gym activity since last 6 months

Exclusion Criteria:

* Individuals who are highly trained in gymnastic
* Already trained (any gym activity or regular exercise)
* Individuals with Diabetes, hypertension, and kidney diseases.
* Any neurological complication
* Any Musculoskeletal Disorder

Primary outcomes:
measure: Quality of Life SF-36 questionnaire
timeFrame: Changes from the baseline to 4th Week
measure: Oxygen Saturation (SpO2)
timeFrame: 4th Week
measure: Pulse Rate
timeFrame: 4th Week
measure: Modified Borg Scale of Perceived Exertion
timeFrame: 4th week
measure: Systolic and diastolic blood pressure
timeFrame: 4th week
measure: VO2 max
timeFrame: 4th week
measure: METS
timeFrame: 4th Week
measure: Quick Physical Activity Rating (QPAR) scale
timeFrame: 4th Week
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Fitlytics gym Rawalpindi
state: Punjab
Study officials:
affiliation: Riphah International University
name: Muhammad Iqbal Tariq, MSCPPT
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05804825: Testing the Persuasiveness of Pro-inoculation Arguments
Official title: Message Testing Protocol for Misinformation Concerns
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Vaccination Hesitancy
Human Papillomavirus Vaccination
Vaccine Refusal
Keywords: misinformation
HPV vaccine
vaccine hesitancy
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
First posted: 2023-04-07
Enrollment: 523
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: randomized discrete choice modeling experiment design
Primary purpose: OTHER

Brief summary: The investigators will recruit a national sample of parents of 7-10-year-olds to complete an argument strength ranking for either a simple forwarding message or between 3 and 6 randomly selected arguments from an overall set of 50 to 100 messages identified from various online sources. Parents will rate each message they see on measures of perceived argument strength/PME. Parents will also answer sociodemographic questions and then rank the believability of a set of anti-vaccine messages identified in a different study. Study findings will contribute valuable information to understanding the effectiveness of different inoculation messages.


Eligibility criteria: Inclusion Criteria:

1. Male or female parent or legal guardian of an adolescent ages 7-10
2. Age eligible child has not yet received any doses of the HPV vaccine
3. Resides in the United States
4. English speaking
5. Completed informed consent

Exclusion Criteria:

1. Unable to read English at a 6th grade literacy level
2. Age \< 18
3. Does not have a child within the age range of 7-10
4. Age-eligible child has received 1 or more doses of the HPV vaccine
5. Does not have a social media account on one or more of the following platforms OR does not read online news stories: Twitter, Instagram, YouTube, Facebook (feasibility testing only - survey participation will not have this exclusion criteria)
6. Unwilling or unable to provide informed consent to study participation

Primary outcomes:
measure: Argument strength/PME
timeFrame: The outcome measure will be assessed immediately after the participant has viewed each pro-HPV vaccine message if they are in the multiple message condition, or the simple message if they are in the simple message condition stimuli during the survey.
measure: Misinformation believability
timeFrame: The outcome measure will be assessed immediately after the participant has viewed each misinformation message during the survey.
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: UPenn
state: Pennsylvania
Study officials:
References: